| Particulars (Rupees in Crores.) | Sept-2025 | Mar-2025 | Sept-2024 | Mar-2024 | Sept-2023 |
|---|---|---|---|---|---|
Gross Sales | 307.83 | 296.02 | 263.07 | 286.96 | 272.21 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 307.83 | 296.02 | 263.07 | 286.96 | 272.21 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 26.09 | 42.69 | 13.96 | 22.01 | 39.82 |
Total Income | 333.92 | 338.71 | 277.03 | 308.97 | 312.03 |
Total Expenditure | 326.8 | 314.94 | 270.06 | 293.15 | 286.08 |
PBIDT | 7.12 | 23.77 | 6.97 | 15.82 | 25.95 |
Interest | 3 | 2.03 | 1.85 | 1.67 | 1.91 |
PBDT | 4.12 | 21.74 | 5.12 | 14.15 | 24.04 |
Depreciation | 16.73 | 17.4 | 17.41 | 17.92 | 18.79 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 0.03 | 0.01 | 0 | 0.69 | 0 |
Deferred Tax | -2.59 | 1.88 | -1.12 | -0.27 | 2.56 |
Reported Profit After Tax | -10.05 | 2.45 | -11.17 | -4.19 | 2.69 |
Minority Interest After NP | -0.18 | -0.35 | 0 | -0.33 | 0 |
Net Profit after Minority Interest | -9.87 | 2.8 | -11.17 | -3.86 | 2.69 |
Extra-ordinary Items | 13.99 | 30.48 | 5.51 | 5.52 | 27.95 |
Adjusted Profit After Extra-ordinary item | -23.86 | -27.68 | -16.68 | -9.38 | -25.26 |
EPS (Unit Curr.) | -1.62 | 0.46 | -1.8 | 0 | 0.44 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 2.31 | 8.02 | 2.64 | 5.51 | 9.53 |
PBDTM(%) | - | - | - | - | - |
PATM(%) | -3.26 | 0.82 | -4.24 | -1.46 | 0.98 |
Such a contract symbolizes Panacea Biotec's continued commitment toward global health by contributing its share of the fight against polio, a deadly disease prevalent in many pockets of the world.
Panacea Biotec's stock has seen a 37% gain over the past six months. Panacea Biotec's stock has gained a total of 76% in the last one year.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.